Pemigatinib

What is Pemigatinib?

Pemigatinib is an innovative oral medication classified as a kinase inhibitor. It is a targeted therapy designed to treat specific types of cancer by blocking the activity of certain proteins that promote cancer cell growth. Approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), Pemigatinib represents a significant advancement in the treatment of cancers driven by specific genetic alterations.

This medication is primarily used in patients whose cancers have a particular genetic mutation, specifically involving the fibroblast growth factor receptor (FGFR). By precisely targeting these altered pathways, Pemigatinib aims to offer a more effective treatment option with potentially fewer side effects compared to traditional chemotherapy, though it is not without its own set of considerations.

How Does it Work?

Pemigatinib functions as a potent and selective FGFR inhibitor. The fibroblast growth factor receptor (FGFR) family consists of four receptor tyrosine kinases (FGFR1, 2, 3, and 4) that play crucial roles in various cellular processes, including cell growth, survival, differentiation, and angiogenesis (formation of new blood vessels). In healthy cells, the FGF/FGFR pathway is tightly regulated.

However, in certain cancers, genetic alterations such as fusions, rearrangements, or mutations in the FGFR genes can lead to uncontrolled activation of this pathway. This aberrant signaling drives tumor cell proliferation and survival. Pemigatinib works by binding to and inhibiting FGFR1, FGFR2, and FGFR3, thereby blocking the downstream signaling pathways that fuel cancer growth. This action effectively halts the proliferation of tumor cells that are dependent on activated FGFR signaling, leading to tumor regression or stabilization. Its precise mechanism makes it a true targeted therapy, focusing on the molecular drivers of the disease rather than broadly attacking fast-growing cells.

Medical Uses

Pemigatinib is indicated for the treatment of specific cancers that harbor FGFR gene alterations. Its primary approved use is for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with an FGFR2 fusion or other rearrangement. Cholangiocarcinoma is a rare and aggressive cancer, and the presence of FGFR2 fusions in a subset of patients provides a critical target for therapy.

Beyond cholangiocarcinoma, Pemigatinib is also approved for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. These are rare blood cancers that can affect various blood cell types. Clinical trials continue to explore the potential utility of Pemigatinib in other cancers driven by FGFR alterations, highlighting its importance in precision oncology.

Dosage

The standard recommended dosage of Pemigatinib is 13.5 mg taken orally once daily for 14 consecutive days, followed by 7 days off treatment, comprising a 21-day cycle. This cycle is repeated as long as the patient benefits from the treatment and does not experience unacceptable toxicity. It is crucial to take Pemigatinib exactly as prescribed by a healthcare professional.

The tablets can be taken with or without food. Patients should swallow the tablets whole and not crush, chew, or split them. Dosage adjustments may be necessary based on the patient's tolerance to the drug and the severity of any side effects experienced. Dose reductions or temporary interruptions may be implemented to manage adverse reactions. Patients with severe renal or hepatic impairment may also require specific dose modifications, which should be determined by their treating physician.

Side Effects

Like all medications, Pemigatinib can cause side effects. Many of these are manageable, but some can be serious. Common side effects include:

• Hyperphosphatemia (high phosphate levels in the blood)
• Alopecia (hair loss)
• Diarrhea or constipation
• Fatigue
• Nausea and vomiting
• Stomatitis (inflammation of the mouth)
• Dry eyes and other ocular toxicities
• Nail toxicity (e.g., brittle nails, nail discoloration)
• Arthralgia (joint pain)
• Abdominal pain
• Dry mouth

More serious side effects can include ocular toxicity, such as retinal pigment epithelial detachment or dry eye syndrome, which can lead to vision changes. Regular eye exams are often recommended during treatment. Hyperphosphatemia is also a significant concern, requiring close monitoring of blood phosphate levels and potential dietary modifications or phosphate-lowering medications. Patients should report any new or worsening symptoms to their doctor immediately.

Drug Interactions

Pemigatinib is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. Therefore, it is important to be aware of potential drug interactions:

• Strong CYP3A4 inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Pemigatinib exposure, leading to a higher risk of side effects. Dosage adjustments or alternative medications may be necessary.
• Strong CYP3A4 inducers: Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Pemigatinib exposure, potentially reducing its effectiveness. Concomitant use should generally be avoided.
• Gastric pH-altering agents: Medications that significantly alter gastric pH, such as proton pump inhibitors (PPIs) or H2-receptor antagonists, may affect the solubility and absorption of Pemigatinib. It is advisable to avoid concurrent use or administer Pemigatinib at a different time of day.
• P-glycoprotein (P-gp) substrates: Pemigatinib is also an inhibitor of P-gp. Co-administration with P-gp substrates (e.g., digoxin, dabigatran) may increase the concentrations of these drugs.

Patients should inform their healthcare provider about all prescription, over-the-counter, and herbal supplements they are taking to avoid potentially harmful interactions.

FAQ

Is Pemigatinib a chemotherapy drug?

No, Pemigatinib is not a traditional chemotherapy drug. It is a targeted therapy that works by specifically inhibiting certain proteins (FGFRs) involved in cancer growth, rather than broadly killing rapidly dividing cells.

How long do I need to take Pemigatinib?

Pemigatinib is typically taken as long as the treatment is effective and tolerable, or until disease progression. Your doctor will monitor your response and side effects to determine the duration of treatment.

What types of cancer does Pemigatinib treat?

Pemigatinib is approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and for adults with relapsed or refractory myeloid/lymphoid neoplasms with an FGFR1 rearrangement.

What are the most important side effects to watch for?

Key side effects to monitor include ocular toxicities (vision changes, dry eyes) and hyperphosphatemia (high blood phosphate levels). Regular eye exams and blood tests are important during treatment.

Can I take Pemigatinib with food?

Yes, Pemigatinib can be taken with or without food. It is important to swallow the tablets whole and not to crush, chew, or split them.

Products containing Pemigatinib are available through trusted online pharmacies. You can browse Pemigatinib-based medications at ShipperVIP or Medicenter.

Summary

Pemigatinib represents a vital treatment option for patients battling specific cancers driven by FGFR gene alterations, particularly advanced cholangiocarcinoma and certain myeloid/lymphoid neoplasms. As a highly effective FGFR inhibitor, it exemplifies the power of precision medicine, offering a targeted approach to disrupt cancer cell proliferation. While generally well-tolerated, awareness of its potential side effects, especially ocular toxicities and hyperphosphatemia, and drug interactions is crucial for safe and effective management. Patients considering or undergoing Pemigatinib treatment should maintain open communication with their healthcare team to ensure optimal outcomes and manage any adverse effects effectively.